Details for Patent: 10,570,202
✉ Email this page to a colleague
Which drugs does patent 10,570,202 protect, and when does it expire?
Patent 10,570,202 protects INLYTA and is included in one NDA.
Protection for INLYTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-nine patent family members in twenty-two countries.
Summary for Patent: 10,570,202
| Title: | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| Abstract: | The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1. |
| Inventor(s): | Martini; Jean-Francois Andre (Carlsbad, CA), Tarazi; Jamal Christo (San Diego, CA), Perini; Rodolfo Fleury (Philadelphia, PA), Mauro; David J. (North Wales, PA) |
| Assignee: | Pfizer Inc. (New York, NY) Merck Sharpe & Dohme Corp. (Rahway, NJ) |
| Application Number: | 15/115,730 |
|
Patent Claim Types: see list of patent claims | Use; Device; Dosage form; |
Recent additions to Drugs Protected by US Patent 10,570,202
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | INLYTA | axitinib | TABLET | 202324 | Jan 27, 2012 | RX | Yes | ⤷ Subscribe | ⤷ Subscribe | U-2844 | IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,570,202
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-001 | Jan 27, 2012 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-002 | Jan 27, 2012 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,570,202
| PCT Information | |||
| PCT Filed | February 03, 2015 | PCT Application Number: | PCT/US2015/014212 |
| PCT Publication Date: | August 13, 2015 | PCT Publication Number: | WO2015/119930 |
International Family Members for US Patent 10,570,202
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015214390 | ⤷ Subscribe | |||
| Brazil | 112016017256 | ⤷ Subscribe | |||
| Canada | 2937521 | ⤷ Subscribe | |||
| Canada | 3210360 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
